EGFR and non-small cell lung carcinoma: A previous study reported that there was a higher incidence of BMs in patients with EGFR-mt NSCLC, and most BMs occurred within 3 years from the initial diagnosis of NSCLC regardless of EGFR mutation status.15 Consistent with this report, our findings underscore the prevalence of BM development during the first 2–3 years following the diagnosis of NSCLC.